company background image
CUS0 logo

Curis DB:CUS0 Stock Report

Last Price

€10.00

Market Cap

€58.9m

7D

8.7%

1Y

0.8%

Updated

25 Mar, 2024

Data

Company Financials +

CUS0 Stock Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

CUS0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Curis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Curis
Historical stock prices
Current Share PriceUS$10.00
52 Week HighUS$17.74
52 Week LowUS$7.06
Beta3.76
1 Month Change16.96%
3 Month Changen/a
1 Year Change0.81%
3 Year Change-94.76%
5 Year Change-71.26%
Change since IPO-99.44%

Recent News & Updates

Recent updates

Shareholder Returns

CUS0DE BiotechsDE Market
7D8.7%2.8%1.3%
1Y0.8%35.3%6.4%

Return vs Industry: CUS0 underperformed the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: CUS0 underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is CUS0's price volatile compared to industry and market?
CUS0 volatility
CUS0 Average Weekly Movement32.4%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: CUS0 has not had significant price volatility in the past 3 months.

Volatility Over Time: CUS0's weekly volatility has increased from 20% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200049Jim Dentzerhttps://www.curis.com

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.

Curis, Inc. Fundamentals Summary

How do Curis's earnings and revenue compare to its market cap?
CUS0 fundamental statistics
Market cap€58.91m
Earnings (TTM)-€43.88m
Revenue (TTM)€9.28m

6.4x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CUS0 income statement (TTM)
RevenueUS$10.02m
Cost of RevenueUS$39.71m
Gross Profit-US$29.68m
Other ExpensesUS$17.73m
Earnings-US$47.41m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-8.04
Gross Margin-296.17%
Net Profit Margin-473.04%
Debt/Equity Ratio0%

How did CUS0 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.